DRYS is an undervalued stock. It is trading so cheap. DRYS owns 78% of ORIG. This alone should bring DRYS price to $1 and higher and assuming ZERO for tanker and drybulk business. We all know tanker business and drybulk is worth hundreds of millions of dollars.
suggestion, I think Elite should start manufacturing the ' elite cups' in India and cut a deal with walmart. then in a few months they can qualify for Nasdaq
If you have some of that you should probably get rid of it before they start bumping interest rates. Be happy that you made anything on it. Just my humble opinion.
That's good, Pops. However, what is flummoxing is that HLF longs seem to have selective memory; that is, HLF will make a change, and you guys will act like the change has been in effect forever. FTC can punish for past sins, you know.
For one quick example, see HLF's return policy.
Now I'm ready to add...................$50K at 2pm today.
BTW.................didn't we have a much lengthier discussion, where are all the posts I made ?
Ziopharm Oncology Announces Dosing of First Patient in Phase 3 Study of Palifosfamide for the Treatment of Small Cell Lung Cancer
June 11, 2012
NEW YORK, June 11, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the first patient has been dosed in the MATISSE study (Multicenter Adaptive Trial Investigating Small cell lung cancer Survival Endpoints), a pivotal Phase 3 multi-center, open-label, adaptive, randomized study of palifosfamide for the treatment of small cell lung cancer. ZIOPHARM has also recently announced the completion of enrollment in its Phase 3 study of palifosfamide in combination with doxorubicin for the treatment of metastatic soft tissue sarcoma in the front-line setting (PICASSO 3).
Mechanism of action: Palifosfamide is a synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lysine for stability, palifosfamide irreversibly alkylates and cross-links DNA through GC base pairs, resulting in irreparable 7-atom inter-strand cross-links; inhibition of DNA replication and cell death follow. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide.
Phase of Development: III
Event Type: Data: Phase III trial results
Dates: 2015-06-01 - 2015-07-31
Over 500 people enrolled......
Sentiment: Strong Buy
Oh, so you're confusing the Bazant paper with the NIST report.
And you still can't name even ONE engineer free of conflicts of interest who is willing to endorse NIST's tower collapse sequence.
Meanwhile I can name 2,355 architects and engineers who are putting their professional reputations on the line by calling for new investigations.
First Samsung. Now Goldman Sachs. ;)
Sybs not telling you to generate argument or speculation or for your wacko parrott input. Sybs doesnt know why sybby botherz, You never listen anyway.... More for a told ya so sybs supposez now.
Btw, just the elimination of those two charges gets GPM back into the black. Not by a lot, but still black.
So, that's good, because those are hopefully in the "one time" category.
Sentiment: Strong Buy